GILD Stock - Gilead Sciences Inc.

GILD Stock Chart

GILD Profile

Gilead Sciences, Inc., headquartered in Foster City, California, is a prominent biopharmaceutical company that focuses on discovering, developing, and commercializing innovative medicines to address critical unmet medical needs globally. Established in 1987, Gilead operates extensively across the United States, Europe, and other international markets.

The company's robust product portfolio includes pioneering treatments in several therapeutic areas. Gilead is renowned for its advancements in HIV/AIDS management, offering a range of medications such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. Additionally, amid the coronavirus pandemic, Gilead introduced Veklury, an intravenous injection for the treatment of COVID-19.

Further bolstering its therapeutic offerings, Gilead provides innovative treatments for liver diseases, including Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. The company also plays a pivotal role in oncology and hematology with products like Yescarta, Tecartus, Trodelvy, and Zydelig, which emphasize its commitment to advancing cell therapy and cancer treatment.

In addition to its robust pipeline of proprietary medications, Gilead Sciences collaborates extensively with leading biotechnology and pharmaceutical companies worldwide. These partnerships, with entities such as Bristol-Myers Squibb, Galapagos NV, and Merck & Co., reflect Gilead's strategy to leverage collective expertise and resources to drive innovation and broaden therapeutic capabilities in its quest to improve patient outcomes.

GILD Revenue Chart

GILD Earnings

Analyst Ratings